Equivalent Survival for Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia  by Moore, John et al.
E
A
M
I
(
r
b
Biology of Blood and Marrow Transplantation 13:601-607 (2007)
 2007 American Society for Blood and Marrow Transplantation
1083-8791/07/1305-0001$32.00/0
doi:10.1016/j.bbmt.2007.01.073quivalent Survival for Sibling and Unrelated Donor
llogeneic Stem Cell Transplantation for Acute
yelogenous Leukemia
John Moore,1 Ian Nivison-Smith,2 Kim Goh,3 David Ma,1 Ken Bradstock,4 Jeff Szer,5 Simon Durrant,6
Anthony Schwarer,7 Peter Bardy,8 Richard Herrmann,9 and Anthony Dodds1
1Haematology Department, St. Vincent’s Hospital, 2Australasian Bone Marrow Transplant Recipient Registry,
Darlinghurst, NSW, Australia; 3National University of Malaysia, Kuala Lumpur, Malaysia; 4BMT Service,
Westmead Hospital, Westmead, NSW, Australia; 5Bone Marrow Transplant Service, Department of Clinical
Haematology and Medical Oncology, Royal Melbourne Hospital, Parkville, Victoria, Australia; 6Haematology
Department, Royal Brisbane Hospital, Brisbane, Queensland, Australia; 7Haematology Department, Alfred
Hospital, Prahran, Victoria, Australia; 8Haematology Department, Royal Adelaide Hospital, Adelaide, South
Australia; and 9Haematology Department, Royal Perth Hospital, Perth, Western Australia
Correspondence and reprint requests: John Moore, MBBS, MD, FRACP, FRCPA, Haematology Department,
St. Vincent’s Hospital, Darlinghurst, NSW Australia (e-mail: jmoore@stvincents.com.au).
Received April 6, 2006; accepted January 15, 2007
ABSTRACT
Recent studies have shown comparable survival outcomes for unrelated donor (URD) stem cell transplantation
in chronic myelogenous leukemia compared to sibling donors. We compared outcomes for 105 patients aged
16 to 59 years undergoing URD transplants for acute myelogenous leukemia (AML) who were reported to the
Australasian Bone Marrow Transplant Recipient Registry between 1992 and 2002, and a strictly selected
matching set of 105 HLA-matched sibling donor (MSD) transplants. There was no significant difference
between URD and MSD controls in the distributions of time from diagnosis to transplant, donor-recipient sex
match, prior therapies, donor age, or performance status. The median follow-up of live URD patients was 4.4
years and for live MSD controls was 6.3 years. There were 18 good risk (complete remission [CR]1) and 87
poor risk (>CR1) recipients in both URD and sibling groups. Five-year disease-free survival (DFS) was not
significantly different for good-risk URD and sibling donor recipients (62% versus 40%, P  .2), or poor-risk
URD and sibling recipients (21% versus 25%, P  .2). In a stratified multivariate Cox regression model, the
independent adverse risk factors for DFS were recipient cytomegalovirus positivity (P  .01) and the interac-
tion of URD and earlier year of transplant (P  .006). Both neutrophil and platelet engraftment were
significantly more rapid in the sibling group, but transplant-related mortality at 100 days was not significantly
different. There was no difference in the cumulative incidence of acute graft-versus-host disease grade II or
above at 100 days. Relapse occurred in 28% of good risk URD subjects and 16% of siblings (P .3), and in poor
risk subjects 39% and 29%, respectively (P  .2). Based on this data, URD allografts should be considered in
AML patients without a matched sibling donor. This study provides a rationale for a larger prospective study
of risk factors in allogeneic transplantation for AML and a guide on the subset of patients who may most benefit
from an unrelated donor allograft in AML.
© 2007 American Society for Blood and Marrow Transplantation
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GNTRODUCTION
Allogeneic hemopoietic stem cell transplantation
HSCT) is a potentially curative procedure in a wide
ange of hematologic malignancies [1]. It is generally
elieved that the major beneﬁt of allogeneic HSCT is freduction in relapse presumably on the basis of the
raft-versus-leukemia (GVL) effect. Acute myeloge-
ous leukemia (AML) is one hematologic malignancy
hat has been demonstrated to be susceptible to this
VL effect, making it the most common indicationor allogeneic transplant in Australasian and Interna-
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I. Nivison-Smith et al.602ional registries [2]. Allogeneic HSCT is often recom-
ended for patients with intermediate risk AML in
rst complete remission (CR1) who have an HLA
dentical sibling match. The toxicity of the procedure,
owever, can offset the reduction in relapse making
he decision to perform allografting in CR1 contro-
ersial [3]. In contrast, allogeneic HSCT is likely to be
he only curative procedure for AML patients beyond
R1, and in this setting both unrelated donor (URD)
nd matched sibling donor (MSD) HSCT are widely
sed [4].
Given that only 30% of patients have a potential
LA MSD, it is likely that the use of histocompatible
RD may increase the potential donor pool for pa-
ients that are considered eligible for allogeneic
SCT. URD HSCT has, however, historically been
erceived to be associated with a higher transplant-
elated mortality (TRM) and lower disease-free sur-
ival (DFS) [5]. In contrast to chronic myelogenous
eukemia (CML) where studies have demonstrated
quivalent outcomes using MSD and MUD donors in
ertain circumstances [6], there is very little data on
he use of MUD donors in AML. More recently, the
se of peripheral blood stem cells (PBSC) and high-
esolution HLA typing have made the use of alterna-
ive donors a realistic choice [7]. In this study we have
irectly compared the outcome of MSD and MUD
onor allografts for AML in 7 Australian centers and
ave found that when matched for disease stage and
ge the outcomes are equivalent.
ATIENTS AND METHODS
tudy Design
The study was a retrospective matched case-his-
oric control design. Transplant recipients were se-
ected for this study using the Australasian Bone Mar-
ow Transplant Recipient Registry, which captures
etails on more than 95% of HSCT carried out in
ustralia and New Zealand each year. Study subjects
n  105) were aged between 16 and 59 years at
ransplant, and were treated with a ﬁrst allograft for
ML from HLA-A, -B, and -DR identical unrelated
olunteer donors. In general, serologic typing was
sed for HLA-A and -B, whereas molecular typing
as used for HLA-DR B1. Subjects received unma-
ipulated transplants between the years of 1992 and
002 inclusive, at 1 of the 7 Australian hospitals that
articipated in this study. Study controls were se-
ected, 1 per subject, from 450 patients receiving their
rst allogeneic transplant for AML from HLA-A, -B, and
DR identical sibling donors from 1992 to 2002 at 1 of
he same centers. Study controls were matched with
ubjects using a hierarchy of disease stage at trans-
lant, recipient age, and sex. Age and disease stage at
ransplant were selected as stratifying factors because rf their strong and well documented effects on sur-
ival [2,8-11]. Sex was chosen as the third stratifying
actor to minimize any chance of unintentional bias in
election of the controls. Where there was a choice of
ore than 1 control, a random algorithm was used to
elect 1. The close-out date was December 31, 2004.
n initial request for data was made in 2003, with data
nalyzed in June 2005.
efinitions
Deﬁnitions used in this study follow IBMTR
uidelines unless otherwise speciﬁed. Good risk dis-
ase was deﬁned as patients in CR1 at the time of
ransplantation, whereas poor risk disease was deﬁned
s patients beyond CR1, including patients in CR2,
rst relapse, and other disease stages as outlined in
able 1. Cytogenetic abnormalities at diagnosis were
lassed as good, t(8;21)(q22;q22), inv(16)(p13q22),
(15;17)(q22;q12), intermediate (normal karyotype
nd all other), or poor risk (monosomy of 5 or 7, 3q,
r complex karyotype). Patients were considered
valuable for engraftment and acute graft-versus-host dis-
ase (aGVHD) if they survived at least 21 days after
SCT. Patients who survived longer than 100 days
osttransplant were considered evaluable for chronic
VHD (cGVHD). Day of neutrophil engraftment
as deﬁned as the ﬁrst of 3 consecutive days when the
lood neutrophil count was 0.5  109/L. Day of
latelet engraftment was deﬁned as the ﬁrst day when
he blood platelet count was 20  109/L and there
ad been no platelet transfusions in the previous 7
ays. TRM was deﬁned as deaths in the ﬁrst 100 days
osttransplant from all causes other than relapse or
ersistent disease. GVHD was classiﬁed as acute when
ccurring up to 100 days posttransplant, and chronic
fter this time. Grading of aGVHD was carried out
ccording to criteria used by IBMTR. Performance
tatus at transplant was deﬁned as good (Karnofsky
erformance scale of 80% or greater, or ECOG per-
ormance status of 0-1), or poor otherwise.
nalysis Methods and Software Used
Differences between groups were assessed using
ither a Mann-Whitney U-test for continuous vari-
bles, or in the case of categoric variables, chi-squared
est, or Fisher’s exact test as appropriate. aGVHD and
elapse incidence were determined using cumulative
ncidence curves, treating death as a competing risk.
verall survival (OS) and DFS were calculated using
aplan-Meier product limit estimates, and differences
etween groups were assessed with the log-rank test.
ifferences between groups in incidence of GVHD in
peciﬁc organs were assessed using chi-squared tests.
Multivariate analysis was carried out to ﬁnd the
igniﬁcant factors affecting OS, DFS, incidence of
elapse, and incidence of aGVHD. The following fac-
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Survival for Allogeneic Stem Cell Transplant for AML 603ors were considered as independent variables in an
nitial univariate analysis: donor type (unrelated/sib-
ing), cytogenetic abnormalities at diagnosis, length
f time to remission postinitial treatment, length of
ime between diagnosis and transplant, year of trans-
lant, donor sex, donor and recipient cytomegalovirus
CMV) status, stem cell source, pretransplant condi-
ioning regimen, GVHD prophylaxis, and cell doses
8,9,11,12]. Interaction terms for donor type (sibling/
nrelated) with all other independent variables were
lso tested.
The signiﬁcance of the above factors on OS, DFS,
ncidence of relapse, and incidence of acute GVHD
as assessed using stratiﬁed multivariate Cox regres-
ion analysis, with disease stage at transplant, recipient
ge, and sex as the strata. Independent variables with
onsigniﬁcant effects were progressively eliminated
rom the model by backward selection using likeli-
ood ratio tests. In all tables, the P-value has been
able 1. Characteristics of Subjects and Controls
Unrelated
10
ood risk (CR1 at transplant) (n) 1
oor risk (>CR1 at transplant) (n) 8
CR2 2
1st Relapse 2
Other 3
ge: median (range) 35 (16-
ex (n)
Male 5
Female 4
ransplant 1992-1996 (n) 3
ransplant 1997-2002 (n) 7
ytogenetic abnormalities
Good 1
Intermediate 3
Poor 4
Not done 2
ource of stem cells (n)
Bone marrow 9
PBSC
MarrowPBSC
onor-recipient CMV status (n)
Neg-Neg 2
Neg-Pos 3
Pos-Neg 1
Pos-Pos 2
retransplant conditioning (n)
CyTBI 9
BuCy
Other
VHD prophylaxis (n)
CSPMTX 8
CSP only
CSPMTXother 1
CSPother
ucleated cell dose  108/kg 2.9 (0.17
D34 dose  106/kg 3.1 (0.9-
BSC indicates peripheral blood stem cells; GVHD, graft-versus-hisplayed as .0005 when statistical output displayed lt as 0, and .9 when displayed as 1. All tests were 2
ailed. Power calculations were carried out using
ASS 2005 statistical software. Survival curves were
roduced using Graphpad Prism Version 3.0. Cumu-
ative incidence curves were produced using NCSS
004 statistical software. Statistical difference tests
nd multivariate Cox regressions were carried out
sing SPSS Version 12.0 statistical software.
ESULTS
atient and Disease Characteristics
The ﬁnal study group comprised 105 subjects
URD recipients) and 105 controls (sibling donor re-
ipients). The subjects and controls were well matched
or disease stage, age, and sex, with no statistically
igniﬁcant differences in any of these parameters
Table 1). At this time, the median follow-up time for
r Sibling Donor P
105 —
18 ns
87
16
41
30
35 (16-58) ns
56 ns
49
49 0.03
56
17 ns
38
29
21
59 <.0005
41
5
20 .02
24
10
51
18 <.0005
74
13
79 .002
13
11
2
3.2 (0.08-23.3) <.0005
4.3 (0.5-14.7) .02
ease.Dono
5
8
7
3
5
9
59)
6
9
3
2
0
2
2
1
9
5
1
5
7
4
9
8
3
4
7
0
7
1
-19.7)
10)ive URD subjects was 4.4 years (range: 369 days-9.2
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I. Nivison-Smith et al.604ears), and for live MSD controls, 6.3 years (range:
62 days-10.9 years). There were no statistically sig-
iﬁcant differences between subjects and controls in
he distributions of cytogenetic abnormalities at diag-
osis, length of time from diagnosis to transplant,
onor-recipient sex match, prior therapies, donor age,
r performance status at transplant (Table 1).
URD transplants were more likely to be after
997, and bone marrow was more commonly used as
he stem cell source (P  .0005). The proportion of
MV negative donors was signiﬁcantly higher among
RD transplants (P  .02). The proportion of cyclo-
hosphamide-total body irridiation (Cy-TBI) condi-
ioning among URD transplants was higher than
mong siblings (P  .0005). Cyclosporin alone was
ore commonly used in sibling donor recipients (P 
002). The median cell doses for both total nucleated
ells and CD34 cells were signiﬁcantly lower for
RD recipients than for siblings (P  .0005).
ransplant Outcome
Both neutrophil and platelet engraftment were
igniﬁcantly more rapid in the sibling group (Table 2).
RM at 100 days was not signiﬁcantly different be-
ween groups for patients in CR1, or beyond CR1.
here were also no signiﬁcant differences between the
roups in the incidence of other adverse events such as
nterstitial pneumonitis, veno-occlusive disease, hem-
rrhagic cystitis, or CMV infection posttransplant.
here was no difference in the cause of death, includ-
ng relapse, GVHD, and infection, in the ﬁrst year
ost transplant between the unrelated and sibling do-
or groups.
ncidence of Acute GVHD
The cumulative incidence of aGVHD Grade
I-IV in evaluable patients at day 100 posttransplant
as 59% for good-risk URDs versus 50% for good-
isk siblings (P  .5), and 55% for poor-risk URDs
ompared with 44% for poor-risk sibs (P  .1). There
as a signiﬁcantly increased incidence of GVHD
able 2. Transplant Outcomes
Unrela
ays to neutrophil engraftment: median (range)
ays to platelet engraftment: median (range)
ransplant related mortality (n, %)
CR1
Not in CR1
verall survival at 5 years
CR1
Not in CR1
isease-free survival at 5 years
CR1
Not in CR1rade II-IV of the skin in the URD recipients (P 0005, Table 3). A stratiﬁed Cox regression analysis
as carried out on the incidence of aGVHD testing
he independent variables and interactions as listed in
he Methods section. No combination of factors had a
igniﬁcant effect on the incidence of aGVHD.
ncidence of Chronic GVHD
The cumulative incidence of cGVHD at 1 year
osttransplant was 94% for good-risk URD trans-
lants and 61% for good-risk sibs (P  .04), and 68%
or poor-risk URD compared with 79% for poor-risk
ibs (P  .4). The rates of cGVHD among patients
live at day 100 posttransplant is shown in Table 3.
ncidence of Relapse
The cumulative incidence of hematologic relapse
t 2 years posttransplant for patients in CR1 at the
ime of transplant was 28% for URD and 16% for
iblings (P  .3), whereas for those beyond CR1, 39%
nd 29% (P  .2). A stratiﬁed Cox regression analysis
as carried out on the incidence of hematologic re-
apse testing the effects of independent variables as
isted in the Methods section. No combination of
actors had a signiﬁcant effect on the incidence of
ematologic relapse.
able 3. GVHD for Patients Who Survived 21 Days
osttransplant
MUD
(n  96)
Sibling
(n  96) P
cute GVHD
Skin 74 (77%) 52 (54%) .001
Liver 26 (27%) 24 (25%) ns
Gut 24 (25%) 30 (31%) ns
Skin stage 2 or higher 48 (50%) 21 (22%) <.0005
Liver stage 2 or higher 17 (18%) 17 (18%) ns
Gut stage 2 or higher 11 (11%) 20 (21%) ns
hronic GVHD
Limited 12 (12.5) 8 (8.3) ns
Extensive 40 (41.7) 47 (48.9) ns
UD indicates matched unrelated donors; GVHD, graft-versus-
nor (n  105) Sibling Donor (n  105) P
0-34) 17 (9-41) .04
-55) 19 (10-45) <.0005
%) 3 (3%) ns
4%) 17 (16%) ns
% 40% ns
% 31% ns
% 40% ns
% 25% nsted Do
18 (1
28 (8
0 (0
25 (2
69
24
62host disease.
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Kaplan-Meier curves for all URD and MSD pa-
ients are illustrated in Figure 1. At 5 years the DFS
or all MSD and URD patients was 31.5% and 29%,
espectively (P  .6). For patients in CR1 at the time
f transplant, the 5-year OS posttransplant was 69%
or URD and 40% for siblings (P .2). Because of the
ow numbers (n  18) in these 2 groups the power of
his comparison is low (40%) so the ﬁnding of non-
igniﬁcance is expected. and results can only be taken
s indicative. For those not in CR1, the 5-year OS
osttransplant was 24% for URD and 31% for sib-
able 4. Signiﬁcant Independent Risk Factors for Overall and Disease-
Factor
verall survival
CMV status: recipient positive
Interaction: unrelated donor  year of transplant 1992-1996
isease-free survival
CMV status: recipient positive
Interaction: unrelated donor  year of transplant 1992-1996
ndependent variables initially included in a univariate model but r
sibling), cytogenetic abnormalities at diagnosis, length of time
transplant, year of transplant, donor sex, donor and recipient C
prophylaxis, nucleated cell dose, and CD34 cell dose.
igure 1. Kaplan-Meier curve of DFS (a) and overall survival (b) in
RD and MSD allogeneic HSCT for AML.MV indicates cytomegalovirus; GVHD, graft-versus-host disease; RR, rings (P  .2) (Table 2). Stratiﬁed Cox multivariate
egressions were carried out on OS and DFS testing
he effects of the independent variables listed above.
he only signiﬁcant adverse risk factors were recipient
MV positivity and the interaction factor of URD
nd earlier year (1992 to 1996) of transplantation
Table 4).
ISCUSSION
This retrospective matched case-control led study
as demonstrated similar outcomes for allogeneic
SCT in AML using either a sibling or URD. This is
ne of the few studies to compare these different
onor sources in the context of AML and has impli-
ations for the use of URD donors in AML. Results
rom the multivariate analysis suggest that the use of a
MV positive recipient and transplantation from
992-1996 using an URD are the major adverse fac-
ors for both DFS and OS. Although this study pre-
ominantly assessed patients with advanced AML, it
ppears that the use of a URD particularly in a CMV-
egative recipient in recent years is a valid therapeutic
ption in the treatment of AML patients.
There have been few studies directly comparing
he use of adult URD and sibling donors in HSCT for
eukemia. Weisdorf et al [6] examined this question in
he context of CML using the NMDP database and
emonstrated that the outcome was similar between
SD and URD when patients 30 years received an
llograft within 1 year of diagnosis while in the
hronic phase. This study was one of the ﬁrst to
onﬁrm a role for URDs for this disease. More re-
ently, the use of imatinib [13] has decreased CML as
n indication for HSCT, leaving AML as the major
ndication for unrelated and sibling donor transplan-
ation. In this AML study there was no difference in
urvival between both good- and poor-risk URD and
SD recipients. The study was, however, not pow-
red to assess the difference in CR1 because of the
mall numbers. Larger numbers are required to con-
rvival—Results of Multivariate Analysis
RR 95% CI P
1.741 (1.189, 2.549) .004
1.711 (1.121, 2.613) .01
1.602 (1.109, 2.313) .01
1.800 (1.188, 2.728) .006
d because of lack of statistical signiﬁcance: donor type (unrelated/
ssion post initial treatment, length of time between diagnosis and
tus, stem cell source, pretransplant conditioning regimen, GVHDFree Su
emove
to remi
MV staelative risk; CI, conﬁdence interval.
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I. Nivison-Smith et al.606rm the ﬁndings in this analysis, particularly for those
atients in CR1.
In 1997, Szydlo et al [5] compared IBMTR data
romMSD and URD transplants in acute lymphoblas-
ic leukemia (ALL), AML, and CML patients. The
ata from this trial compared outcomes only from
atients transplanted before 1991 and showed a higher
RM and a lower DFS in the unrelated setting. This
tudy is difﬁcult to compare to this current AML study
iven that many patients were mismatched at both
lass I and II antigens, and there was no matching for
ge or disease stage. An Austrian study also assessed
onor source in allogeneic HSCT for AML [11]. This
as not a matched cohort study and contained only 40
RD patients; however, a multivariate analysis did
onﬁrm that donor source was not a major prognostic
actor for DFS. Eapen et al [14] conﬁrmed that the use
f URD donors in infants with AML in CR1 was
ustiﬁed given the equivalent survival of MSD and
RD allografts. The role of MUD donors in AML
as also been assessed in the nonmyeloblative setting
y Bertz et al [15]; however. there was no comparative
ibling cohort. Recently, the French Society of Bone
arrow Transplantation and Cell Therapy have dem-
nstrated similar survival for URD and MSD in
ML, myelodysplastic syndromes (MDS), and acute
eukemia [16]. This study also conﬁrmed the impor-
ance of positive recipient CMV serology in outcome.
The major limitation of this study is the retrospec-
ive cohort design. The MSD and URD donors were
arefully matched for age and disease stage, which
ere believed to be important prognostic factors
ased on the CML allogeneic HSCT data [6] and
revious AML studies [9]. The lack of cytogenetics in
1% of patients is of uncertain importance but may
ave had some effect on outcome. There were other
igniﬁcant differences between the 2 groups, in that
RD HSCT more frequently used Cy/TBI condi-
ioning, bone marrow as the stem cell source, and
MV-negative donors. The latter 2 factors are deter-
ined by the physician’s preference or guidelines for
he use of granulocyte-colony stimulating factor
G-CSF) in normal donors in some registries. It is
ifﬁcult to determine whether these factors may have
ffected the results of this analysis. Large randomized
rials have previously conﬁrmed the equivalence of
y/TBI and Cy/Bu conditioning regimens in AML
17]. Likewise, bone marrow and peripheral blood
tem cells have previously been compared in Austra-
ian centers [18] with no clear advantage found, sug-
esting that these factors would not have had a major
mpact on the conclusions from this data.
The multivariate analysis conﬁrmed that CMV
erostatus of the recipient is an important adverse
rognostic factor in the allogeneic HSCT setting.
everal other studies have also reported this observa-
ion in allogeneic HSCT trials [19]; however, the datas more deﬁnitive in the T cell-depleted setting [20].
he second adverse factor outlined in the multivariate
nalysis is the interaction of URD and transplantation
n the ﬁrst half of the study period (1992-1996). It is
nclear why this is the case, but it is possible that
etter supportive care, including newer antifungals
nd the increased use of high-resolution HLA typing
ay have improved URD transplantation since 1996.
urther studies will be required to clarify this
nding.
Although this study only has signiﬁcant power to
ake conclusions about advanced AML, it would ap-
ear that transplantation from both a URD and a
atched sibling have equivalent outcomes in this pa-
ient group. The results of this analysis suggest that
RD HSCT should be considered early in the deci-
ion-making process for patients with AML. Further
tudies are required to conﬁrm subgroups of patients
ho may most beneﬁt from URD allografting in AML.
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